Core Insights - Eli Lilly's stock experienced a rise of over 2% following positive news regarding a potential blockbuster drug and an expansion of manufacturing capabilities [1] Drug Development - Eli Lilly's next-generation obesity drug, orforglipron, may receive FDA approval by the end of this year due to a fast-tracked review process [2][3] - The FDA's new program allows investigational drugs to be reviewed in 1-2 months, significantly shorter than the standard 10-month review period [3] - Analysts believe orforglipron is a strong candidate for this expedited process as it addresses a high-burden chronic condition and can be competitively priced [4] Manufacturing Expansion - Eli Lilly plans to build a new manufacturing facility in Virginia, with an estimated cost of $5 billion, focusing on antibody-drug conjugates [4] - This Virginia plant is part of a broader capital expansion initiative, with Eli Lilly committing $50 billion to various projects, including factory construction, since 2020 [5]